Irisin
Irisin (FNDC5 cleavage product)
112 Amino Acids · MW: ~12.3 kDa
Amino Acids
112
Molecular Weight
~12.3 kDa
Half-life
hours
Research Score
5.0
Studies
79
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Irisin?
Irisin is a cleavage product of FNDC5 that has been studied for exercise-linked improvements in glucose homeostasis and energy expenditure. It can influence AMPK, SIRT1, and PGC-1α signaling in metabolic tissues.
Key Benefits & Mechanisms
glucose homeostasis
energy expenditure
brown-fat activation
Research Summary
Irisin is widely explored in obesity and type 2 diabetes research because it connects exercise biology with metabolic adaptation. Human findings are mixed, so it remains a biomarker and preclinical lead rather than an approved therapy.
Related Peptides
Insulin Lispro
Insulin lispro (B28-Lys, B29-Pro human insulin analog)
A rapid-acting insulin analog with a reversed B28/B29 sequence that speeds absorption after subcutaneous injection. It is used to reduce postprandial hyperglycemia and to support flexible mealtime insulin strategies.
Diabetes & MetabolicInsulin Aspart
Insulin aspart (B28-Asp human insulin analog)
A rapid-acting insulin analog with an amino-acid substitution at B28 that promotes faster absorption after injection. It is widely used to blunt postprandial glucose excursions in diabetes research and clinical practice.
Diabetes & MetabolicInsulin Glargine
Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)
A long-acting basal insulin analog engineered for slow release from the subcutaneous depot. It provides relatively flat day-long insulin coverage and is used to control fasting glucose.
Diabetes & MetabolicInsulin Degludec
Insulin degludec (desB30, acylated ultra-long-acting insulin analog)
An ultra-long-acting insulin analog designed with a fatty-acid side chain to form a slow-release depot. It is valued for very flat pharmacokinetics and flexible once-daily basal dosing.
Diabetes & Metabolic